Mochammad Saiful Bachri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mochammad Saiful Bachri has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arde Toga Nugraha
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Yogyakarta, Indonesia
1 shared publication - Danang Prasetyaning Amukti
Alma Ata University, Yogyakarta, Indonesia
1 shared publication - Deni Setiawan
Universitas Lambung Mangkurat
1 shared publication Dwi Utami
Universitas Ahmad Dahlan
1 shared publication- Fitri Apriliany
Department of Pharmacy, Faculty of Medicine, Bumigora University, Mataram, West Nusa Tenggara, Indonesia
1 shared publication - Laela Hayu Nurani
Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
Identification of Potential Drug Leads from Dendrobium stuartii Through Integrated In Silico, Phytochemical, and Pharmacological Methods
The genus Dendrobium is a rich source of bioactive secondary metabolites, particularly bibenzyl derivatives with substantial pharmacological activities, but Dendrobium stuartii remains an underexplored species. Therefore, this study aimed to investigate the drug discovery potential of D. stuartii through an integrated in silico and experimental method. Four key compounds were prioritized through literature analysis, and the interactions with the epidermal growth factor receptor (EGFR) were evaluated using molecular docking. The chemical profile of the acetone extract was characterized using Liquid Chromatography–High Resolution Mass Spectrometry (LC-HRMS). Additionally, biological activities were assessed through antibacterial, antibiofilm, and anti-inflammatory assays. Batatasin III had the strongest predicted binding affinity toward EGFR, and the LC-HRMS analysis confirmed the presence of bibenzyl derivative 3,4ʹ-dihydroxy-5,5ʹ-dimethoxybibenzyl (gigantol). The extract provided antibacterial activity, specifically against S. aureus and P. acnes , inhibited biofilm formation during the mid-phase, and produced substantial anti-inflammatory activity, as evidenced by significant inhibition of protein denaturation. The results suggested D. stuartii as a promising underexplored source of bioactive compounds with potential applications in anticancer and anti-infective drug development.
- 16 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
Open AccessIdentification of Potential Drug Leads from Dendrobium stuartii Through Integrated In Silico, Phytochemical, and Pharmacological Methods
The genus Dendrobium is a rich source of bioactive secondary metabolites, particularly bibenzyl derivatives with substantial pharmacological activities, but Dendrobium stuartii remains an underexplored species. Therefore, this study aimed to investigate the drug discovery potential of D. stuartii through an integrated in silico and experimental method. Four key compounds were prioritized through literature analysis, and the interactions with the epidermal growth factor receptor (EGFR) were evaluated using molecular docking. The chemical profile of the acetone extract was characterized using Liquid Chromatography–High Resolution Mass Spectrometry (LC-HRMS). Additionally, biological activities were assessed through antibacterial, antibiofilm, and anti-inflammatory assays. Batatasin III had the strongest predicted binding affinity toward EGFR, and the LC-HRMS analysis confirmed the presence of bibenzyl derivative 3,4ʹ-dihydroxy-5,5ʹ-dimethoxybibenzyl (gigantol). The extract provided antibacterial activity, specifically against S. aureus and P. acnes , inhibited biofilm formation during the mid-phase, and produced substantial anti-inflammatory activity, as evidenced by significant inhibition of protein denaturation. The results suggested D. stuartii as a promising underexplored source of bioactive compounds with potential applications in anticancer and anti-infective drug development.
- Open Access
- 30 May 2025
- Published by Universitas Muhammadiyah Palangkaraya in Borneo Journal of Pharmacy
- Vol. 8 (2) , 127-134
Purple Yam (Dioscorea alata) Extract Increasing Dopamine Levels and Improving the Brain's Microscopic Features in Parkinson's Model Mice
Parkinson's disease (PD) is a severe neurodegenerative disorder, that causes progressive motor issues from the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc). Purple yam (Dioscorea alata), rich in anthocyanins, shows promise as a natural antioxidant and neuroprotectant. This study investigated the antiparkinsonian effects of D. alata extract on dopamine levels and brain microscopic features in a haloperidol-induced PD mouse model. Thirty-five male mice were randomly allocated into seven groups: normal (CMC-Na and aqua pro injection), haloperidol-induced negative control (CMC-Na), positive control (levodopa 39 mg/kgBW), curcumin (200 mg/kgBW), and D. alata extract-treated groups (100, 200, and 400 mg/kgBW). Treatments were administered daily for seven days. On day 8, all groups, except the normal control, received an intraperitoneal injection of haloperidol (2 mg/kgBW) to induce Parkinsonism. Three hours post-haloperidol injection, dopamine levels were measured from orbital vein blood. Subsequently, brains were harvested for histological examination of the SNpc using Toluidine blue staining. Data were statistically analyzed using one-way ANOVA followed by LSD post-hoc tests. The 400 mg/kgBW dose of D. alata extracts significantly increased dopamine levels (p<0.05) compared to the negative control group. Microscopic analysis of the SNpc in mice treated with 400 mg/kgBW extract revealed preserved, dark, and solid neuronal morphology, with significantly higher scoring results (p<0.05) when compared to the levodopa-treated group. These findings suggest that D. alata extract, particularly at a dose of 400 mg/kgBW, exhibits potential antiparkinsonian activity by elevating dopamine levels and mitigating dopaminergic neuronal damage in a haloperidol-induced PD mouse model.
- 30 May 2025
- Published by Universitas Muhammadiyah Palangkaraya in Borneo Journal of Pharmacy
- Vol. 8 (2) , 127-134
Open AccessPurple Yam (Dioscorea alata) Extract Increasing Dopamine Levels and Improving the Brain's Microscopic Features in Parkinson's Model Mice
Parkinson's disease (PD) is a severe neurodegenerative disorder, that causes progressive motor issues from the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc). Purple yam (Dioscorea alata), rich in anthocyanins, shows promise as a natural antioxidant and neuroprotectant. This study investigated the antiparkinsonian effects of D. alata extract on dopamine levels and brain microscopic features in a haloperidol-induced PD mouse model. Thirty-five male mice were randomly allocated into seven groups: normal (CMC-Na and aqua pro injection), haloperidol-induced negative control (CMC-Na), positive control (levodopa 39 mg/kgBW), curcumin (200 mg/kgBW), and D. alata extract-treated groups (100, 200, and 400 mg/kgBW). Treatments were administered daily for seven days. On day 8, all groups, except the normal control, received an intraperitoneal injection of haloperidol (2 mg/kgBW) to induce Parkinsonism. Three hours post-haloperidol injection, dopamine levels were measured from orbital vein blood. Subsequently, brains were harvested for histological examination of the SNpc using Toluidine blue staining. Data were statistically analyzed using one-way ANOVA followed by LSD post-hoc tests. The 400 mg/kgBW dose of D. alata extracts significantly increased dopamine levels (p<0.05) compared to the negative control group. Microscopic analysis of the SNpc in mice treated with 400 mg/kgBW extract revealed preserved, dark, and solid neuronal morphology, with significantly higher scoring results (p<0.05) when compared to the levodopa-treated group. These findings suggest that D. alata extract, particularly at a dose of 400 mg/kgBW, exhibits potential antiparkinsonian activity by elevating dopamine levels and mitigating dopaminergic neuronal damage in a haloperidol-induced PD mouse model.